UAB Neurology study adds to evidence that massive, second-wave reaction kills nerve cells.
Written by Greg Williams
The finding may help to avert more of the bleeds and blood clots that come when a patient’s starting dose misses the drug’s narrow safety window.
Work may provide insight into drug design for autism, movement disorders.
Investigators studying a long-acting injectable formulation of aripiprazole, a partial dopamine agonist.